Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill
A not-for-profit organisation dedicated to encouraging life sciences R&D has launched a new tool to help companies in the sector design better apps and digital tools.
Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
